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ABSTRACT
The transcription factor Pax-5, is vital during B lym-
phocyte differentiation and is known to contribute to
the oncogenesis of certain cancers. The Pax-5 locus
generates multiple yet structurally related mRNA
transcripts through the specific activation of alter-
native promoter regions and/or alternative splicing
events which poses challenges in the study of spe-
cific isoform function. In this study, we investigated
the function of a major Pax-5 transcript, Pax-5B
using an enhanced version of the Hepatitis Delta
Virus ribozyme (HDV Rz) suppression system that
is specifically designed to recognize and cleave
the human Pax-5B mRNA. The activity of these ribo-
zymes resulted in the specific suppression of the
Pax-5B transcripts without altering the transcript
levels of other closely related Pax-5 isoforms
mRNAs both in vitro and in an intracellular setting.
Following stable transfection of the ribozymes into a
model B cell line (REH), we showed that Pax-5B sup-
pression led to an increase of CD19 mRNA and cell
surface protein expression. In response to this
Pax-5B specific deregulation, a marked increase in
apoptotic activity compared to control cell lines was
observed. These results suggest that Pax-5B has
distinct roles in physiological processes in cell fate
events during lymphocyte development.
INTRODUCTION
Recent studies have demonstrated that the Pax gene
family controls gene expression activity at the transcrip-
tion level and regulates fundamental cellular processes
such as proliferation, diﬀerentiation and cell death
events (apoptosis) (1,2). Given their essential role in
cell biology, deregulated Pax genes also act as oncogenes
and have the potential to transform normal cells into their
cancerous counterparts (2,3). A well-studied member of
this family, Pax-5, is known to encode the B-cell speciﬁc
activator protein (BSAP) which is expressed in the
embryonic central nervous system, B lymphocytes, and
adult testis (4). In the past decade, the interest in the
Pax-5 transcription factor has been drawn to its pivotal
role in B-cell lymphogenesis (5,6). Pax-5 requirement to B
commitment is highlighted by its transcriptional control
over key events that are essential for B-cell development
and activation. Studies have identiﬁed a number of Pax-5
target genes several of which are known to modulate the
expression of B-cell receptor (BCR) components and asso-
ciated proteins (i.e. CD19, blk etc.) (7,8). Pax-5 selective
pressure to B-cell commitment is also conveyed by its abil-
ity to negatively regulate non-conforming pathways of the
B lineage leading to the diﬀerentiation of non-B cellular
development (9,10).
At the genetic level, human Pax-5 is mapped to chro-
mosome 9 in region p13 where it is regulated by two dis-
tinct promoters regions: ﬁrst a TATA-containing
upstream promoter associated with an exon 1A, and a
TATA-less downstream promoter coupled with an exon
1B. Through regulated signaling processes along with the
recruitment of speciﬁc transcriptional regulators, each
promoter induces the transcription of a distinct 50UTR
region and a ﬁrst exon which then splices to a coding
sequence (exons 2–10) common to both transcript iso-
forms (11,12). These two mRNAs (noted Pax-5A and
Pax-5B) are discriminated only by their unique 50UTR
sequence and exon 1 of the coding region (Figure 1A).
Although a great number of studies have contributed to
the functional characterization of Pax-5 at the molecular
and cellular level, few have discriminated between the
physiological roles of Pax-5A and Pax-5B isoforms
individually. Given the fact that most Pax-5 bearing cells
express both Pax-5 isoforms simultaneously (almost a 1:1
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alternatively spliced products has proven to be complex
and very challenging. As a result, little attention has been
paid to the cellular characterization of Pax-5B. Therefore,
we set out to develop a Pax-5B gene suppression system
using a modiﬁed ribozyme (Rz) technology to investigate
the speciﬁc roles associated with Pax-5B in human B
lymphocytes.
The ability of a ribozyme to speciﬁcally recognize, and
subsequently catalyze the cleavage of an RNA target
makes it an attractive molecular tool for the development
of gene inactivation systems (13). It provides an interest-
ing alternative to an RNA-interference (RNAi) approach
in functional genomics, especially given the recent ﬁndings
that RNAi speciﬁcity is limited and evidence shows that
this mechanism can trigger immunological response
(14,15). The ribozyme isolated from the hepatitis delta
virus (HDV Rz) appears to be the most suited to develop
a gene-inactivation in human cells since it has evolved
within this particular cell environment (13). In support
of this, results have shown this catalytic RNA to be
fully active in physiological concentrations of magnesium
in human cells (16). However, the target recognition
mechanism of the HDV Rz is dependant on the formation
of a 7 base pair (bp) between the Rz and the substrate,
(namely the P1 stem/Figure 1B). It has been estimated that
a minimum sequence of 15 or 16 base pairing nucleotides
are required for the targeting of unique RNA species in
the human transcriptome, thereby limiting non-speciﬁc
cleavage (17). In order to fulﬁll these parameters, a new
generation of HDV Rz was engineered which incorporates
a Speciﬁc On/ofF Adaptor (SOFA) that switches the
cleavage activity from oﬀ to on solely in the presence of
the appropriate substrate (Figure 1B) (18,19). A unique
feature of the SOFA-HDV Rz allows it to limit the cata-
lytic activity via a blocking sequence that prevents the
folding of the ribozyme into an active conformation.
This ‘safety lock’ function prevents cleavage of a substrate
that contains an appropriate P1 stem but lacks a comple-
mentary sequence to the SOFA biosensor. This new
target-dependent module biosensor bearing Rz signiﬁ-
cantly reduces non-speciﬁc cleavage events.
In this study, we developed an isoform-speciﬁc SOFA-
HDV Rz capable of recognizing and cleaving human
Pax-5B transcripts both in vitro and in vivo. Using this
gene suppression system, we report that the Pax-5B tran-
scriptional element is associated with changes in target
gene activation as well as to the balance of cell fate
events in human B lymphocytes.
MATERIALS AND METHODS
Plasmids and ribozyme DNA constructs
The Pax-5A cDNA was cloned as described previously
(20). The Pax-5B transcript was cloned into pBlueScript
(SK) (Stratagene, Cedar Creek, Texas) through an
RT-PCR ampliﬁcation on RNA extracts from Ficoll-
isolated PBLs (peripheral blood lymphocytes) using spe-
ciﬁc primers Pax-5B sense 50-CCGATGGAAATACAC
TGTAAGC-30 and Pax-5B antisense 50-CTCCAAGG
GTCAGTGACGG-30. The Pax-5B insert was then sub-
cloned into the pcDNA3.1 expression vector (Invitrogen,
Burlington, Ontario, Canada) using a directional cloning
technique involving the XhoI, XbaI and NotI restriction
sites depending on the insert’s original orientation.
Pax-5B speciﬁc SOFA-HDV Rz were constructed as
described previously (18). Brieﬂy, SOFA-HDV Rz were
constructed using a PCR-based strategy that included
two complementary and overlapping oligodeoxynucleo-
tides: the antisense oligonucleotide 50-CCAGCTAG
AAAGGGTCCCTTAGCCATCCGCGAACGGATGC
CC(ANNNNNN)P1ACCGCGAGGAGGTGGACCCTG
(N)4-BL-30 (where N is A, C, G or T, P1 and BL indicate
the P1 strand region and the blocker sequence, respec-
tively) and, the sense 50-TTAATACGACTCACTA
TAGGGCCAGCTAGTTT(N)12-BS(N)4-BLCAGGGTCC
ACC-30 (where N is A, C, G or T, BS indicates biosensor
sequence and BL the blocker sequence, respectively) that
permitted the incorporation of the T7 RNA promoter
(underlined). It is important to note that the (N) segments
vary in sequence depending on the targeted site accessible
on the target RNA substrate (Table 1). The DNA coding
SOFA-HDV Rz were rendered double stranded by PCR
which were later puriﬁed by phenol:chloroform extraction,
precipitated with ethanol and dissolved in water. The
double-stranded DNA (dsDNA) fragments were either
used for in vitro transcriptions (described below), or
cloned without the T7 promoter region into a polymerase
III-based expression vector psiRNA-hH1-GFP/Zeo
(Invivogen, San Diego, CA, USA).
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Figure 1. Schematic structure of the human Pax-5 gene and the
SOFA-HDV Rz (A) The human Pax-5 gene located on chromosome
9 includes two alternative promoter regions (empty boxes\promoters A
and B) which regulate the expression of exclusive exon regions (solid
boxes) 1A and B, respectively, followed a common exons 2–10
sequence. The dotted diagonal lines indicate the spliced regions from
the mature coding transcripts. (B) The structure of the SOFA-HDV Rz
adopts an oﬀ (left panel) and locked conﬁguration secured by the
blocker stem in the absence of its speciﬁc mRNA target (Pax-5B). In
the presence of the speciﬁc substrate (right panel) the SOFA-HDV Rz
adopts a catalytically active conﬁguration which is formed through
the annealing of the ribozyme’s biosensor (BS) and P1 stem (P1) to
the target substrate. These structures were previously described in
(18,19).
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Both SOFA-HDV Rz and substrates were synthesized by
run-oﬀ transcription from PCR products and HindIII
linearized pcDNA3.1-Pax-5B templates, respectively, as
described previously (18). Brieﬂy, transcriptions were per-
formed in the presence of puriﬁed T7 RNA polymerase
(10mg), RNA Guard (24U, Amersham Biosciences), pyr-
ophosphatase (0.01U, Roche Diagnostics, Laval, QC,
Canada) and either linearized plasmid DNA (5mg) or
PCR product (2–5mM) in a buﬀer containing 80mM
HEPES-KOH pH 7.5, 24mM MgCl2, 2mM spermidine,
40mM DTT, 5mM of each NTP in a ﬁnal volume of
100mla t3 7 8C for 2–4h. Upon completion, the reaction
mixtures were treated with DNase RQ1 (Amersham
Biosciences, Piscataway, NJ) at 378C for 20min, the
RNA puriﬁed by phenol:chloroform extraction and then
precipitated with ethanol. The RNA products were frac-
tionated by denaturing (6 or 10%) polyacrylamide gel
electrophoresis (PAGE; 19:1 ratio of acrylamide to bisa-
crylamide) in buﬀer containing 45mM Tris-borate pH 7.5,
7M urea and 1mM EDTA. The reaction products were
visualized either by UV shadowing or autoradiography.
The bands corresponding to the correct sizes for both
the SOFA-HDV Rz and substrate RNA molecules were
cut out and the transcripts eluted overnight at room tem-
perature. The transcripts were desalted on Sephadex G-25
(Amersham Biosciences) spun-columns, and were then
ethanol precipitated and quantiﬁed by absorbance at
260nm.
Ribozyme cleavage assays
The conditions for the SOFA-HDV Rz cleavage assays
have been described previously (18). Brieﬂy, in all reac-
tions the ribozymes and substrate were preincubated
together at 378C for 2–5min; thereafter, the magnesium
was added to initiate the cleavage reaction. Reactions were
performed using 1mM HDV Rz and trace amounts of
50-terminal [
32P]-labeled substrate at 378C in a ﬁnal
volume of 10ml containing 50mM Tris–HCl pH 7.5 and
5mM MgCl2. Experiments were incubated at 378C for
2.5h, stopped by the addition of ice-cold formamide dye
buﬀer (5ml of 97% formamide, 10mM EDTA pH 8.0,
0.025% xylene cyanol and 0.025% bromophenol blue),
electrophoresed on an 8% PAGE gel and exposed
onto a PhosphorImager screen (Molecular Dynamics,
Sunnyvale, CA, USA).
Cells lines andtransfections
HEK293 and 293T cells (human embryonic kidney) were
obtained from the American Type Culture Collection
(Rockville, MD, USA) and the REH (acute lympho-
cytic leukemia cells) cell line was kindly provided by
Dr Edward A. Clark, University of Washington Medical
Center, Seattle. We also made of HEK293 stably trans-
fected with the full length human Pax-5B coding region,
the HEK 293-B2 cell line, which was created in our
laboratory. Cell lines were maintained in complete culture
medium made of DMEM (HEK) or RPMI-1640 (REH)
supplemented with 10% fetal bovine serum (FBS; Hyclone
Laboratories, Logan, UT, USA), L-glutamine (2mM),
penicillin G (100U/ml), and streptomycin (100mg/ml)
(Invitrogen). Cells were either left untreated or treated
(as described in ﬁgure legends) with 2mMo f
Actimomycin D (Sigma, St Louis, Missouri).
Transient transfections of the HEK cell lines and stably
transfected REH cells were conducted using the
Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s instructions. Brieﬂy, cells were seeded into
6-well plates (2 10
5/well) where they received a total of
2mg (or indicated otherwise) of plasmid DNA that was
complexed with the provided transfection reagent.
Northern Blothybridizations
Northern blot analyses were performed as described pre-
viously (18) using 10mg of RNA isolated by Trizol
TM
(Invitrogen). The Pax-5B probe was obtained by a T3
RNA polymerase-based transcription in the presence of
[a-
32P]UTP on a pBlueScript Pax-5B construct. The
-actin RNA probe used was prepared using the Strip-
EZ
TM RNA T7/T3 kit (Ambion, Austin, TX, USA). All
hybridizations were carried out for 16–18h at 658C. The
membranes were then exposed to PhosphorImager screens
for 2–24h and thereafter analyzed on a radioanalytic scan-
ner (Storm, Amersham Biosciences).
Preparation ofnuclear extracts andelectrophoretic
mobility shift assays (EMSA)
Nuclear extracts were prepared according to the pre-
viously described microscale preparation protocol and
analyzed by gel shift assays previously described (20).
Brieﬂy, cells (5 10
6) were washed with ice-cold PBS
and resuspended in 400ml of cold buﬀer A [10mM
N-2-hydroxyethylpiperazine-N0-2-ethanesulfonic acid
(HEPES; pH 7.9), 10mM KCl, 0.1mM EGTA, 0.1mM
EDTA, 1mM DTT, and 0.5mM phenylmethylsulfonyl
ﬂuoride (PMSF)]. The cells were allowed to swell on ice
for 15min, after which 25ml of a 10% solution of Nonidet
P-40 was added and the tube was vigorously vortexed for
30s. The homogenate was centrifuged for 10s at 12000g.
The supernatant fraction was discarded and the pellet was
resuspended in 50ml of cold buﬀer C [20mM HEPES-
KOH (pH 7.9), 0.4mM NaCl, 1mM EDTA, 1mM
EGTA, 1mM DTT and 1mM PMSF] and incubated
at 48C for 15min on a shaking platform. Cellular debris
were removed by centrifugation at 12000g for 20min at
48C and the supernatant fractions were stored at  2708C
Table 1. Nucleotide sequences of Pax-5B target regions
SOFA-HDV-Rz Targeted sequence
B75 CCCG/ATGGAA ATACACTGTAAGCACGACCC
B78 GATG/GAAATACACTGTAAGCACGACCCGTT
B89 ACTG/TAAGCACGACCCGTTTGCATCCATGC
B93 TAAG/CACGACCCGTTTGCATCCATGCATAG
B97 CACG/ACCCGT TTGCATCCATGCATAGACAT
(/) indicates the cleavage site of ribozyme.
The complementary sequence to the P1 binding site of the SOFA-
HDV-Rz is indicated in bold.
The complementary sequence to the biosensor of the SOFA-HDV-Rz is
underlined
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to perform EMSA as determined by the bicinchoninic acid
assay (BCA) with a commercial protein assay reagent
(Pierce, Rockford, IL, USA). Nuclear extracts were incu-
bated for 20min at room temperature in 20ml of the bind-
ing buﬀer (100mM HEPES (pH 7.9), 40% glycerol, 10%
Ficoll, 250mM KCl, 10mM dithiothreitol, 5mM EDTA,
250mM NaCl, 2mg poly (dI-dC) and 10mg nuclease-free
bovine serum albumin fraction V) containing 1ng of
32P-50-end-labeled double-stranded (dsDNA) oligonucleo-
tide. Double-stranded DNA (100 ng) was labeled with
[g-
32P]ATP and T4 polynucleotide kinase in a kinase
buﬀer (New England Biolabs, Beverly, MA, USA). This
mixture was incubated for 30min at 378C and the reac-
tions were stopped with 5ml of 0.2M EDTA. The labeled
oligonucleotides were extracted with phenol/chloroform
and passed through a G-50 spin column. The dsDNA
oligonucleotides, which were used as probes, contained
the consensus NF-kB and the BSAP sites corresponding
to the sequences 50-ATGTGAGGGGACTTTCCC
AGGC-30 and 50-GAATGGGGCACTGAGGCGTG-30,
respectively. The DNA-protein complexes were migrated
on a 4% (w/v) polyacrylamide gel containing Tris-Borate-
EDTA. The gels were then subsequently dried and auto-
radiographed. Cold-competition assays were carried out
by adding a 100-fold molar excess of unlabeled dsDNA
oligonucleotide simultaneously with the labeled probe.
Quantitative RT–PCR andmRNA half-life analysis
Levels of gene expression were veriﬁed by quantiative
PCR. Reaction mixtures were composed of 20nM each
sense and antisense primers and 0.1mg of human total
cDNA, diluted in water to a total of 12.5ml and mixed
with 12.5ml of 2X iQ SYBR Green Supermix (BioRad,
Mississauga, Ontario, Canada) where they were run in a
Smart Cycler II real-time PCR apparatus (Cepheid,
Sunnyvale, CA, USA) with the following parameters:
2min initial denaturation, 35 cycles of 1min at 948C,
1min at 558C (optics on), 1min at 728C, followed by
melt curve analysis from 658Ct o9 5 8C. Quantitative
PCR applications were conducted on Pax-5B sense 50-T
TGGCACGAGGTAGACAC-30 and antisense 50-AGCC
CTCCAACACTGAGA-30; SOFA-HDV Rz sense 50-AT
CCATCGGGTACCGGGCCAGCTAGTTT-30 and anti-
sense 50-CCAGCTAGAAAGGGTCCCTTAGCCATCC
GCG-30; and ﬁnally CD19 sense 50-CCACCTGGAGA
TCACTG-30 and antisense 50-ATAAGCCAAAGT
CACAGC-30. Comparative expression levels were calcu-
lated using the iiCt method of Livak and Schmittgen
(21), with the endogenously expressed gene hypoxanthine
ribosyltransferase (HPRT) using sense 50-TGACACTG
GCAAAACAATGCA-30 and antisense 50-GGTCCT
TTTCACCAGCAAGCT-30 primers as the internal con-
trol. Ampliﬁcation eﬃciencies were also considered and
calculated for all real-time ampliﬁcation products (data
not shown). Where applicable, transcript decay rates
were performed through the use of quantitative
RT–PCR on RNA extracts from REH cells treated with
actimomycin-D (2mM) as previously described (22).
Flow cytometry analysis
Cells (10
6) were incubated for 30min on ice with saturat-
ing concentrations (1mg/10
6cells) of PE-conjugated
monoclonal antibodies directed against CD19 or HLA-
DR (BD Bioscience, Mississauga, Ontario, Canada).
Finally, cells were resuspended in 500ml of phosphate-buf-
fered saline (PBS) before ﬂow cytometry analysis (FACS
Calibur, BD Biosciences, Miami, FL, USA). Controls
consisted of commercial isotype-matched irrelevant
murine monoclonal antibodies (Sigma, Oakville,
Ontario, Canada) (10000 events/sample).
Cell proliferation and apoptosis assays
Cells (10
7) were seeded in 96 well plates and analyzed in
time for cellular viability and apoptotic events using a
multiplexed assay of CellTiter Blue (Promega, Madison,
WI, USA) and Apo-One (Promega) assay kits, respec-
tively, according to the manufacturer’s instructions.
Brieﬂy, 20ml of the CellTiter Blue substrate was added
to 100ml of cell suspension and incubated for 1h at
room temperature on a plate shaker. Thereafter, the
plate was subjected to a colorimetric analysis and read
on a ﬂuorescence microplate reader (560Ex/590Em).
Apoptotic events were then measured on the same micro-
plate by the addition of 120ml of Apo-ONE, incubated for
another hour and analyzed by ﬂuorescence (485Ex/527Em).
RESULTS
In order to investigate the functional role of the human
Pax-5B transcription factor, we have developed a RNA-
based gene suppression system which has the ability to
speciﬁcally recognize, bind and cleave an RNA substrate
in a sequence-speciﬁc manner. The speciﬁc SOFA-HDV
Rz were designed to target sequences within the exon 1B
that includes non-translated and coding sequence of the
human Pax-5 gene (Figure 2). Target sequences were iden-
tiﬁed considering the substrate preference of the SOFA-
HDV Rz (i.e. a guanosine residue in position +1 of the
cleavage site, no guanosine in position –1, and no two
consecutive pyrimidines in positions –1 and –2 (23).
Moreover, in order to ensure the substrate speciﬁcity of
the SOFA-HDV Rz, the sequences targeted were analyzed
using RiboSubstrates, an integrated bioinformatics soft-
ware that enables a search of a cDNA database for all
potential substrates for a given ribozyme (24). This
includes the mRNAs that perfectly match the speciﬁc
requirements of a given SOFA-HDV Rz, as well those
including wobble and mismatches base pairings. These
analyses revealed that the designed SOFA-HDV Rz
should solely cleave the Pax-5B mRNAs from the
human transcriptome (data not shown).
SOFA-HDV Rzspecifically cleave their appropriate
human Pax-5RNA substrate in vitro
In vitro cleavage assays were ﬁrst conducted to evaluate
the catalytic potential of each SOFA-HDV Rz directed
against a partial region of the human Pax-5B transcript
(Figure 2). SOFA-HDV Rz directed against the sequence
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mRNA sequence (labeled SOFA-HDV Rz-B75, -B78,
-B89, -B93 and -B97, respectively) were incubated with a
speciﬁc (Pax-5B) as well as with a non-speciﬁc (Pax-5A)
RNA substrate. Following an incubation period, SOFA-
HDV Rz-B75 and B78, eﬃciently recognized and cleaved
their appropriate Pax-5B substrate (i.e. with 25.1 and
25.4% cleavage, respectively) while no observable cleaved
products appeared in the reactions containing the Pax-5A
RNA fragments. In the three other tests, SOFA-HDV Rz
exhibited only minimal cleavage activity ( 1–2%) while
no detectable cleavage of the Pax-5A mRNA was
observed with Pax-5B speciﬁc ribozymes. The absence of
cleavage activity of the Pax-5A-derived transcripts is an
illustration that the SOFA-HDV Rz do not elaborate oﬀ-
target cleavage activity in the presence of non-speciﬁc sub-
strates. Importantly, the in vitro experiments led to the
identiﬁcation of two ribozymes possessing the greatest cat-
alytic activity (SOFA-HDV Rz-B75 and HDV Rz-B78).
SOFA-HDV Rz suppressed Pax-5Bintracellular levels
in adose-dependentmanner
In order to determine the intracellular eﬃciency and cat-
alytic potential of the two selected SOFA-HDV Rz to
target Pax-5B, Northern blot hybridization on Pax-5
negative 293T cells co-transfected with a recombinant
Pax-5B construct and increasing amounts of SOFA-
HDV Rz DNA (10, 100 and 1000ng) were performed
(Figure 3A). The insert encoding the ribozymes were
cloned in a Pol III-driven vector (psiRNA hH1). An
increasing reduction of the intracellular levels of human
Pax-5B transcripts was observed concomitant to increas-
ing amounts of transfected speciﬁc ribozymes in all
cases (Figure 3A and B). The highest concentration of
SOFA-HDV Rz yielded a decrease of the Pax-5B sub-
strate over 50% (Figure 3B). Control samples including
untreated 293T cells, empty expression vectors, and indi-
vidual Pax-5B and SOFA-HDV Rz transfectants were
also included to evaluate ribozyme catalytic activity
(Figure 3A). Thereafter, the same blots were subsequently
hybridized with a human actin probe (Figure 3A, lower
panel) to demonstrate that the decreasing levels observed
in Pax-5B transcript expression were in fact due to speciﬁc
ribozyme cleavage and not a general outcome of messen-
ger RNA degradation following treatment. Evidence
shows that SOFA-HDV Rz are capable of cleaving their
speciﬁc substrate in a dose-dependant manner in an intra-
cellular environment. Finally, Northern blot hybridiza-
tions were also performed using a probe for the speciﬁc
detection of the Pax-5A isoform and no variations of the
mRNA level was detected in the presence of Pax-5B spe-
ciﬁc ribozymes (data not shown). The latter results also
supported the notion that SOFA-HDV Rz do not elicit
oﬀ-target cleavage.
In order to conﬁrm the previous data, we then investi-
gated the eﬀect of mRNA reduction by SOFA-HDV Rz
cleavage on protein expression levels. Since, there are no
known anti-Pax-5B antibodies available, we analyzed
Pax-5B protein levels via its DNA-binding activity by
electrophoretic mobility shifts assays (EMSA). Using
293T cells co-transfected with recombinant Pax-5B and
SOFA-HDV Rz plasmids, the levels of Pax-5B DNA-
binding activity was measured using radiolabeled
dsDNA consensus-binding sites for the Pax-5B transcrip-
tion factor. As shown in ﬁgure 3C, a noticeable shifted
complex in 293T expressing recombinant Pax-5B was
observed while no protein-DNA complexes were detected
in control samples (lanes Probe, 293T, pcDNA and
psiRNA-hH1). More importantly, nuclear extracts from
cells co-expressing Pax-5B with either SOFA-HDV
Rz-B75 or SOFA-HDV Rz-B78, revealed a signiﬁcant
reduction in shifted complex intensity. Control EMSA
experiments were also performed with the same nuclear
extracts incubated with a radiolabeled NF-kB
(Figure 3C, lower panel) DNA consensus-binding site.
NF-kB binding eﬃciencies were not altered in any of the
samples tested. Moreover, the shifted complexes in both
assays were subjected to both speciﬁc and non-speciﬁc
100-fold excess cold competitions, thereby demonstrating
the identity of the protein/DNA complexes.
Next, we wanted to assess SOFA-HDV Rz activity in
cells expressing physiological levels of intracellular Pax-5B
substrates. To accomplish this, a 293-B2 cell clone which
stably expresses the full coding region of human Pax-5B
was generated. Subsequently, these cells were transiently
transfected with increasing amounts of the most eﬀective
ribozyme, SOFA-HDV Rz-B75, (8ng to 4mg) and the
level of Pax-5B mRNA was monitored by quantitative
RT-PCR using primers amplifying a region spanning the
50UTR and the ﬁrst exon of the target substrate
(Figure 4A). We observed a decrease of 76% in Pax-5B
levels as intracellular levels of SOFA-HDV Rz-B75
increased following transfection treatments (Figure 4B).
Conversely, no suppression was observed in control
extract of 293-B2 cells transfected with 4mg of either the
5′UTR exon 1Β
GCCCCGATGGAAATACACTGTAAGCACGACC
P
B75
B78
B89
B93
B97
B75
B78
B89
B93
B97
Ctrl
Pax-5 1Α Pax-5 1Β
Ctrl
S
Rz
Figure 2. Autoradiogram of in vitro cleavage assays showing the
cleavage speciﬁcity of the SOFA-HDV Rz directed against the human
Pax-5B transcript. SOFA-HDV Rz were tailored against the human
Pax-5B mRNA (above sequence) to target nucleotide positions
75, 78, 89, 93 and 97 of the exon 1 region (black arrows). In vitro
cleavage assays were performed using 50 terminal [
32P]-labeled RNA
regions of the human Pax-5A and Pax-5B transcript incubated with
Pax-5B-speciﬁc SOFA-HDV Rz-B75, -B78, -B89, -B93 and -B97 and
then migrated on to a 5% polyacrylamide gel and autoradiographed.
On the right of the panel, ‘S’ indicates the substrates ( 600 bases), ‘Rz’
indicates the SOFA-HDV Rz and ‘P’ indicates the 50 terminal cleaved
products ( 75 and 78 bases).
Nucleic Acids Research, 2008, Vol. 36, No. 14 4613expression vector alone (psiRNA-hH1) or with a non-
speciﬁc functional SOFA-HDV Rz (NS Rz) containing a
mismatched recognition motif unable to recognize the
Pax-5B substrate. As expected, no ribozymes were
detected in cells transfected with the empty vector alone,
whereas increasing amounts of ribozyme expression was
observed in other samples, which corroborated with the
dose-response transfections of SOFA-HDV Rz in the
293-B2 cell line. The levels of Pax-5B were normalized
in relation to the HPRT reference gene.
Using nuclear protein extracts from the cell described
above, we again analyzed Pax-5B DNA-binding suppres-
sion through EMSA analyses. We observed a strong Pax-
5B shifted complex from 293-B2 nuclear extracts in the
absence of SOFA-HDV Rz, while its presence led to a
signiﬁcant reduction of the amount of shifted Pax-5B
complex (data not shown). Moreover, the shift was
shown to be speciﬁc to Pax-5B protein since NF-kB
DNA complexes did not vary in intensity following
SOFA-HDV Rz transfections. Together, these data
demonstrate that the intracellular suppression of Pax-5B
expression is mediated through speciﬁc ribozyme activity
which can be observed at both the transcriptional and
translational levels.
Ribozyme-mediated suppressiondecreases target Pax-5B
mRNA stability in Blymphocytes
In order to investigate the gene suppression activities of
the ribozyme on endogenously expressed Pax-5B, again
the SOFA-HDV Rz-B75 construct was stably transfected
in the REH B-cell line. Zeocin-resistant clones as well as a
mixed population of transfectants were then analyzed by
quantitative RT–PCR to assess SOFA-HDV Rz-mediated
Pax-5B suppression. All ampliﬁed elements were normal-
ized to HPRT expression. Stably transfected cell clones
demonstrated a marked suppression up to 79% (clone
B75-3) of Pax-5B mRNA levels in comparison with the
parental REH cell line (Figure 5A). These REH B75 cell
clones were also compared with a REH cell population
stably transfected with the empty vector alone (psiRNA-
hH1), which did not demonstrate any Pax-5B suppression
activity when compared with the control parental REH
cell line. The fact that Rz-mediated suppression of
Pax-5B was observed in all screened REH B75 cell
clones and in the mixed population of transfected cells
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Figure 3. In vivo evaluation of genetically engineered SOFA-HDV Rz
to suppress the expression levels of the human Pax-5B gene products.
(A) Northern analysis were conducted on RNA extracts from 293T
cells transiently cotransfected with Pax-5B (500ng); increasing amounts
of SOFA-HDV Rz (1, 100 and 1000ng) and ﬁnally ﬁller DNA to
totalize 1.5mg. Individual controls are indicated as the untransfected
cells (293T); cells cotransfected with Pax-5B along with the SOFA-
HDV Rz empty vector (identiﬁed Pax-5B); and cells cotransfected
with SOFA-HDV Rz along with the Pax-5B empty vector (identiﬁed
Rz). Radiolabeled RNA probes were then hybridized onto the mem-
brane to reveal transcript expression levels from intracellular Pax-5B
(top panel) and actin (bottom panel) as an internal reference. (B) The
radioactivity from the hybridized Pax-5B probes was then calculated
and normalized on actin transcripts densities using a radioanalytic
scanner and plotted with error bars in relation to expression ratios
(in black). SOFA-HDV Rz RNA levels are also plotted accordingly
(right of the panel, in white). (C) Electrophorectic Mobility Shift
Assays (EMSA) were conducted on nuclear extracts from 293T cells
cotransfected with Pax-5B and SOFA-HDV Rz. Nuclear extracts were
incubated with either with Pax-5 (top panel) or NF-kB-speciﬁc (bottom
panel) dsDNA oligonucleotides labeled at the 50 end with [g-
32P].
DNA–protein complexes were resolved and analyzed on a 4% polya-
crylamide gel. Speciﬁc (S) and non-speciﬁc (NS) cold competition
(Comp) assays were carried out by adding a 100-fold molar excess of
unlabeled dsDNA oligonucleotides corresponding to the Pax-5 or the
NF-kB consensus-binding motif. Control lanes were loaded with free
probe (Probe) and extracts from untouched 293T cells (293T). Other
controls include transfections of the Pax-5B empty vector (identiﬁed
pcDNA), the Pax-5B expression vector (identiﬁed Pax-5B) and ﬁnally
the SOFA-HDV Rz empty vector (identiﬁed psiRNA).
4614 Nucleic Acids Research, 2008, Vol. 36, No. 14demonstrates the consistent activity of the ribozyme in a B
lymphocyte intracellular environment and rules out a
clonal eﬀect. Stable REH B75 clones were also analyzed
for Pax-5A expression by real-time PCR. As predicted,
we observed no cross-reactive suppression from our
Pax-5B-speciﬁc SOFA-HDV Rz on Pax-5A mRNAs
(Figure 5A). Interestingly, the SOFA-HDV Rz-mediated
knockdown of Pax-5B resulted in an induction of Pax-5A
mRNA expression. These results suggest that Pax-5B
plays a negative role in the trans-activity of other Pax-5
isoforms (i.e. Pax-5A).
Clones of REH cells stably transfected with SOFA-
HDV Rz-B75 were then subjected to quantitative
RT–PCR analysis to examine ribozyme expression in
every REH clone in comparison to the REH parental
cell line. Relatively high expression levels of SOFA-
HDV Rz were observed in every cell population except
for REH cells stably transfected with the empty vector
(psiRNA-hH1) alone (Figure 5B). Since the REH B75-3
cell clone demonstrated the highest attenuation in Pax-5B
levels, this latter cell clone was used in subsequent cellular
and molecular analyses for the functional investigation of
the Pax-5B gene product.
Initially, the speciﬁc mRNA decay rates of Pax-5B
targeted by SOFA-HDV Rz in the REH cell line were
examined. More speciﬁcally, Pax-5B mRNA stability in
SOFA-HDV Rz-B75 bearing REH cells was monitored
and compared with control cell populations (REH and
REH/psiRNA-hH1) in time following a treatment of
2mM actinomycin-D to inhibit mRNA synthesis. This
was done to verify whether or not there were any diﬀer-
ences in global transcript decay rates between the REH
parental cell line and REH transfectants (psiRNA-hH1 or
the SOFA-HDV Rz-B75). For this experiment, relative
amounts of the HPRT mRNA from the diﬀerent cell
line clones were analyzed at various time points by
quantitative RT–PCR analysis (Figure 5C). Following
actinomycin-D treatment, a steady decline of HPRT tran-
scripts was registered up to 12h and these decay rates were
identical in all cell lines tested. The half-lives of HPRT
mRNA were calculated according to the slope which
represented 2.9, 2.2 and 2.6h for the REH, REH/
psiRNA-hH1 and REH B75 cell lines, respectively.
However, in the case where Pax-5B degradation rates
were plotted in time following actinomycin-D treatment,
a signiﬁcant decrease in Pax-5B stability was observed in
B cells containing the SOFA-HDV Rz-B75 construct in
comparison to the control cell lines (Figure 5D). Inter-
estingly, Pax-5B mRNA levels in the REH B75 clones
were nearly undetectable after only 4h of treatment,
whereas these transcripts could still be observed up to
14h in the other control cell lines (REH and
REH/psiRNA-hH1. The Pax-5B mRNA half-life in
REH B cells was calculated at 3.2, 3.3 and 0.7h for the
REH, REH/psiRNA-hH1 and REH B75 cell lines, respec-
tively. These results strongly suggest that this suppression
occurs through speciﬁc SOFA-HDV Rz activity which
accelerates 4-fold the intracellular Pax-5B transcript
degradation, which, in turn, leads to a reduction in
Pax-5B protein activity.
The human Pax-5B transcriptional element negatively
regulates CD19expression
A diﬀerent variant, Pax-5A (BSAP), has been consistently
associated as a transcriptional activator of the CD19 sur-
face antigen and therefore we set out to evaluate the trans-
activation potential of Pax-5B on CD19 expression. Using
REH cells stably expressing SOFA-HDV Rz-B75, the
inﬂuence of Pax-5B on CD19 mRNA expression were
assessed through quantitative RT–PCR (Figure 6A).
Unexpectedly, we observed a 3.6-fold induction of CD19
mRNA expression in the Pax-5B suppressed REH cell
line when compared to both control cell populations
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Figure 4. Pax-5B tailored SOFA- HDV Rz cleave their intracellular
target substrate in a dose-dependent manner. Quantitative RT–PCR
was performed on the 293-B2 cell line (293 HEK cells stably expressing
Pax-5B) transiently transfected with increasing amounts of SOFA-
HDV Rz-B75 DNA to determine (A) Pax-5B transcripts and (B)
SOFA-HDV Rz expression levels. Pax-5B and SOFA-HDV Rz levels
were normalized using HPRT mRNA and plotted in relation to the
relative percentage of the control 293-B2 cell line. Control samples
are also included being the 293-B2 cell line transfected with the
SOFA-HDV Rz empty vector (identiﬁed psiRNA) and a non-speciﬁc
SOFA-HDV Rz (identiﬁed NS Rz) were also tested. Error bars are
indicative of two independent sets of experiments.
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To conﬁrm this ﬁnding, we measured the cell surface
expression of the CD19 protein in the same REH cell
systems (Figure 6B). Using ﬂow cytometry, we were able
to detect expression of the CD19 antigen in all B cells
tested. Concomitant to mRNA levels, the REH B75
cells expressed higher levels of cell surface CD19 up to
6-fold over the REH parental cell line. In order to prop-
erly demonstrate that the induction of CD19 surface
expression was not a result of a generalized increase in
total cell surface receptors, the expression of a cell surface
major histocompatibility complex class II element (HLA-
DR) was examined on all three cellular settings. We found
no variation in the expression of cell surface HLA-DR in
all cell populations tested (Figure 6B). As a further con-
ﬁrmation, ﬂow cytometry for CD19 expression was
also performed on other REH B75-1 and -2 clones and
again, an increase in CD19 expression was observed
following Pax-5B suppression (data not shown). These
results strongly suggest that the human Pax-5B protein
negatively regulates the expression of CD19 in B
lymphocytes.
Pax-5B suppression increases B-cell susceptibility
to apoptotic events
Previous studies have shown that both Pax-5 and CD19
are important regulatory components in B-cell prolifera-
tion and diﬀerentiation (25,26), therefore we sought to
determine if the suppression of Pax-5B expression would
impact cell growth and apoptosis in B lymphocytes.
Cellular metabolic activities were thus examined in time
for REH cells stably expressing the SOFA-HDV Rz-B75
in comparison with the REH parental and the vector-
transfected control. Initially, the various cell lines prolif-
erated at similar rates (Figure 7A). However, after 72h,
the Pax-5B attenuated REH cells ceased to proliferate.
To assess the cause of this growth arrest, we determined
cell death events in these cell lines using a microscale
procedure to measure the activity of apoptosis eﬀectors,
CASPASES 3 and 7 (Figure 7B). We detected no signiﬁ-
cant apoptosis activity in the control REH cells (REH
and vector-transfected) up to 168h (7 days) of growth
in appropriate conditions. Conversely, Pax-5B-suppressed
cells initiated apoptotic signaling cascades after 72h.
The onset of apoptotic events observed in the REH B75
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4616 Nucleic Acids Research, 2008, Vol. 36, No. 14cell line correlated with the proliferation arrest
observed after 72h. To our knowledge, this is the
ﬁrst indication that the human Pax-5B transcriptional
element is involved in the cell fate outcomes of
B lymphocytes.
DISCUSSION
Many recent studies have contributed to the better under-
standing of general Pax-5 function in various biological
processes (5,6); however, few have attempted to discrimi-
nate between the physiological roles of the individual
Pax-5A and Pax-5B variants. The inherent diﬃculty is
largely due to the fact that both genes and proteins are
nearly identical diﬀering only by their ﬁrst exon. Most
studies that examined the role of Pax-5 have relied
mainly on antibodies (27,28), nucleic probes (29,30),
RNAi (31), antisense oligonucleotides (32) and/or site-
directed genetic alteration (33) that target common
regions present in both Pax-5A and Pax-5B. It is, there-
fore, not possible to draw conclusions on the speciﬁc roles
of the individual genes and/or proteins from these pre-
vious works. Recently, the development of gene inactiva-
tion tools has focused on the attenuation or silencing of
target mRNA for the study of gene function. Reliable and
A
R
e
l
a
t
i
v
e
 
C
D
1
9
 
l
e
v
e
l
s
0
100
200
300
400
psiRNA B75 Reh
CD19 HLA-DR
Reh
psiRNA
B75
B
Figure 6. Pax-5B is a negative transcriptional regulator of the CD19
cell surface antigen. (A) Quantitative RT–PCR was conducted
on extracts from the REH, the psiRNA-hH1 and the B75 cell clones
to reveal CD19 intracellular transcript levels. CD19 mRNA values
were normalized using HPRT levels and plotted in relation to
the percentage of CD19 expression levels of the parental untreated
REH cell line. Error bars are indicative of two independent experi-
ments. (B) The cells were evaluated for cell surface protein expression
of CD19 (left panels) and HLA-DR (right panels) using cell-ﬂow
cytometry. The plotted ﬂuorescence from the direct labeling of
the speciﬁc antibodies (empty graphs) is overlaid on the non-
speciﬁc signal from the control isotype matched antibodies (solid
graphs). The presented data represents one of two independent
experiments.
psiRNA
B75
A
20
40
60
80
100
120
140
160
180
Time (hours)
C
e
l
l
 
v
i
a
b
i
l
i
t
y
 
(
%
)
20
40
60
80
100
120
B
A
p
o
p
t
o
s
i
s
 
(
f
o
l
d
 
i
n
d
u
c
t
i
o
n
)
1
2
3
4
5
6
0
20
40
60
80
100
120
140
160
Time (hours)
psiRNA
B75
Figure 7. Pax-5B promotes REH cell survival by suppressing apoptotic
events. (A) Cellular viability was evaluated in time (hours) in the B75
(dotted line) and the control psiRNA-hH1 cell (solid line) clones and
plotted in relation to the percentage of cell growth events from the
REH parental cell line using a colorimetric test (Cell titer Blue/
Promega). (B) In the same microplates, cells were then submitted to
the analysis of cellular apoptotic events through the evaluation of
CASPASE 3/7 activity (Apo-ONE/Promega). Cellular apoptosis for
each cell clone was then plotted in fold induction over the events
measured in the REH parental cell line. Error bars are indicative of
three independent experiments.
Nucleic Acids Research, 2008, Vol. 36, No. 14 4617selective gene suppression systems are a valuable tool to
create loss and gain of function models which provide new
insights for intracellular signaling discovery and pathway
analysis. In this context, the ﬁndings of this study are
signiﬁcant. Here, we validate a novel gene-suppression
system based on a genetically modiﬁed viral ribozyme
for the functional characterization of highly similar gene
products transcribed from the Pax-5 gene locus. This new
gene-silencing approach has allowed us to reveal the
important contribution of the Pax-5B gene during apop-
totic events in human B lymphocytes.
We have recently modiﬁed the native HDV Rz by the
addition of a biosensor for the recognition of its speciﬁc
substrate (18,19). The SOFA-HDV Rz is the only RNA-
based gene suppression system of its kind to function as a
riboswitch and therefore cleave only when the speciﬁc
target mRNA is present. It has been shown previously
that most Pax-5 expressing cells simultaneously produce
multiple Pax-5 isoforms (11,20,34). Therefore, to study
the unique contributions of the diﬀerent gene products,
we developed several SOFA-HDV Rz designed to target
unique regions found in the human Pax-5B exon 1 mRNA
sequence. When tested in vitro and in vivo, these Pax-5B
speciﬁc SOFA-HDV Rz displayed a high level of target
speciﬁcity. In all assays, we observed speciﬁc recognition
and cleavage of the Pax-5B substrate with no suppressive
oﬀ-target eﬀects on the levels of the other major
isoform Pax-5A. More interestingly, in B lymphocytes
co-expressing Pax-5 isoforms, Pax-5A mRNA expres-
sion levels were up-regulated following Pax-5B down-
regulation. These results suggest that Pax-5B plays a
negative role in the transactivity of other Pax-5 isoforms.
These observations are not surprising given the fact that
autoregulation and negative transregulation activities
between Pax-5 variants have been previously reported
(35,36). As a control, we also designed a functional yet
non-speciﬁc SOFA-HDV Rz and when tested in similar
conditions, our results show that this ribozyme does not
aﬀect levels of Pax-5B RNA. Furthermore, the catalytic
activity of the SOFA-HDV Rz was not cell-type depen-
dent since Pax-5B transcript cleavage was observed in
both HEK 293 and REH cells lines.
It is important to note that substrate cleavage occurs via
direct ribozyme activity and is not mediated by RNA
interference since the longest complementary region
between a SOFA-HDV Rz and its Pax-5B substrate is
12bp. We further ruled out the involvment of RNAi path-
way components by gene expression analysis of mRNA
from SOFA-HDV Rz transfected cells which revealed no
activity from any RNAi elements following SOFA-HDV
Rz mediated cleavage of a speciﬁc substrate (unpublished
data; F. Brie ` re, M. Laﬂamme, J.P. Perreault and R.
Ouellette). The dose-dependent catalytic activity of the
SOFA-HDV Rz observed in our transient co-transfections
was not as pronounced when studying transfected B lym-
phocytes. In certain cases using B lymphocytes, the highest
level of gene expression knock-down was observed in
transfected clones with lower cellular concentration of
ribozyme expression. These observations may be due to
substrate accessibility and competition between promoter
elements in our co-transfection settings (23,37).
The reduction of Pax-5B transcript levels had a subse-
quent eﬀect on Pax-5B protein levels which was most
likely due to decreases in synthesis levels. Our ﬁndings
using EMSA assays revealed that ribozyme-mediated
gene silencing led to a concomitant attenuation of the
target protein expression as observed by a decrease in
Pax-5B DNA-binding activity. This reduced binding was
not associated with a general decrease in DNA-binding
activity as revealed by NF-kB control experiments. Our
ﬁndings suggest that high levels of Pax-5B suppression are
incompatible with survival of B cells (REH). Following
selection of stably-transfected REH clones, the maximum
level ribozyme-mediated suppression of Pax-5B was 85%
of control cells. (Figure 5A). Despite numerous attempts,
we were unable to identify any stably-transfected SOFA-
HDV Rz clones with a greater reduction of Pax-5B
expression. These ﬁndings are consistent with our results
of Pax-5B knock-down experiments using RNAi (unpub-
lished data; Robichaud, G.A. and R. Ouellette). In these
experiments, we found that with Pax-5B-directed RNAi
sequences we were able to completely suppress Pax-5B
expression. However, total suppression of Pax-5B led to
complete cell death of REH cells compared to control
REH cells that received a scrambled RNAi sequence.
Taken together, these results strongly suggest that a mini-
mal requirement of Pax-5B expression is required for cell
survival. It also reveals the usefulness of the SOFA-HDV
Rz system as a tool to selectively suppress and study vital
cellular elements.
We then used our Pax-5B-attenuated B-cell system
to study the eﬀects on a known downstream target of
Pax-5A, in this case, the CD19 gene. In previous studies,
the DNA-binding motif of the Pax-5A protein or BSAP
has been shown to bind the CD19 promoter region
via a cluster of proximal Pax-5 recognition sites (7).
Subsequently, this protein–DNA interaction induces
CD19 gene expression which acts as a developmental
checkpoint for early B-lineage commitment (38).
Surprisingly, we observed a marked increase in CD19
expression both at the mRNA and protein levels in our
Pax-5B knockdown B cells which, taken together, imply
that Pax-5B is a negative regulator of CD19. This ﬁnding
is contrary to the positive regulatory eﬀect of Pax-5A on
CD19 observed in previous studies (37). Interestingly,
CD19 is a key molecule in the B lymphocyte signal trans-
duction complex, where it associates with other proteins
including the B-cell antigen complex (BCR) which has
been shown to regulate B-cell fate and function (25,26).
The CD19 surface protein modulates basal signaling
thresholds and accelerates BCR signals thus serving as a
general ‘rheostat’ that deﬁnes downstream signaling criti-
cal for B-cell responses, growth and autoimmunity (26,39).
Furthermore, in certain instances, CD19 has also been
shown to attenuate B-cell activation and proliferation
events (40,41). It is precisely these CD19 events that
could explain the lower proliferation rates observed in
Pax-5B attenuated B lymphocytes.
Previous studies have also demonstrated that a decrease
in the expression of the human Pax-5 gene (with no
discrimination to Pax-5A or Pax-5B) is associated with
decreased B-cell growth rates (28,32). In addition to the
4618 Nucleic Acids Research, 2008, Vol. 36, No. 14lower proliferation rates seen in Pax-5B knockdown cells,
we observed that these B lymphocytes undergo apoptotic
events that are mediated through the activity of
CASPASES 3\7. Apoptosis is a key cellular pathway that
mitigates the production of defective cells that occur
during aberrant cellular processes such as hypersensitivity,
autoimmunity, infection, mutation, anergy and oncogen-
esis (42). Apoptosis is particularly important during the
development of lymphocytes when it removes both ineﬀec-
tive and potentially harmful cells via the withdrawal of
survival signals. Interestingly, Pax-5 expression has been
primarily associated with the development and mainte-
nance of B-cell progenitors, then subsequently decreases
and ceases in terminally diﬀerentiated plasma cells (4,43).
Our ﬁndings suggest that Pax-5B may be closely involved
in the diﬀerentiation checkpoints that ensure the precise
regulation of the development and proliferation programs.
This is consistent with data from Rahman et al. (28), which
show that the suppression of Pax-5 results in the growth
arrest of pre-B cells—results that were not observed in
either pro-B or mature B-cell lines.
Apoptosis also plays a role in the prevention of onco-
genic transformation associated with the development of
cancer. Numerous studies have shown that aberrant
expression of Pax-5 has been associated with the onset
of diﬀerent types of cancers (3,44), whereas others have
also shown that Pax-5 is overexpressed in many types of B
cell lymphoma and lymphocytic leukemia (20,30).
Therefore, it appears that Pax-5 gene products are respon-
sible on the one hand for the promotion B-cell commit-
ment, and on the other, for the homeostasis of cell fate
events. As a key switch in the balance between prolifera-
tion and apoptosis, Pax-5B could represent a potential
target for therapeutic intervention. Further analysis of
other downstream cell-fate regulators and known Pax-5
pathway components [i.e. p53 (45), Ets-1 (46), PD-1 (38)
etc.] will help elucidate the complex networks and cell-fate
events involved in B-cell development and oncogenesis.
We are presently addressing some of these issues.
More recently, we and others have newly identiﬁed and
characterized Pax-5 isoforms which result from the alter-
native splicing of the Pax-5 coding regions (20,34). On a
functional basis, these protein variants possess diﬀerent
transactivation potential and have the ability to interact
with diﬀerent protein partners, and in certain cases, spe-
ciﬁc Pax-5 isoforms have been correlated with diﬀerent
types of cancers (20,47). These ﬁndings begin to address
the complexity of the Pax-5 transcript and protein isoform
function in B lymphocytes. Through the use of isoform-
speciﬁc gene-silencing tools such as SOFA-HDV Rz, we
are now able to better interrogate these regulators
involved in B-cell development, cell-fate events and
oncogenesis.
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